Harmony Biosciences Reports $714M 2024 Revenue For WAKIX; 2025 Forecast $820M-$860M With Potential $1B+; Key Catalysts In Each Quarter; FDA Review For Pitolisant sNDA, Orexin Data, Fragile X Topline, And Narcolepsy Trial; Six Phase 3 Programs Expe...
Harmony Biosciences Holdings, Inc. HRMY | 27.74 | -0.79% |
WAKIX® (pitolisant) Preliminary Net Revenue of ~$201 Million for Fourth Quarter and ~$714 Million for Full Year 2024; Representing Growth of ~23% in Year-Five of Launch
2025 WAKIX Net Revenue Guidance Between $820 - $860 Million; On Track to a Potential $1 Billion+ Opportunity
Value-Creating Catalysts Anticipated Every Quarter in 2025:
Q1 – FDA Decision on File Acceptance of Pitolisant sNDA for Idiopathic Hypersomnia; Potential Approval in 2025
Q2 – Orexin/BP1.15205 Data Presentation at SLEEP 2025 Conference
Q3 – Pivotal Phase 3 Topline Data for ZYN002 in Fragile X Syndrome
Q4 – Initiation of Pitolisant-HD Pivotal Phase 3 Trial in Narcolepsy
Robust, Catalyst-Rich Pipeline Includes Up to Six Phase 3 Clinical Programs by Year End 2025
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced strong preliminary, unaudited net product revenues for Q4 and full year 2024 of $201 million and $714 million, respectively. Building on this performance, the company is well positioned for a catalyst-rich 2025, with value-creating milestones anticipated every quarter. Harmony will be highlighting its catalysts for 2025 and other key milestones during its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 11:15 a.m. PT / 2:15 p.m. ET.